Synthesis and characterization of related substances of Azilsartan Kamedoxomil

N V D Harikiran Maddi1,2, Srinivas Garaga1,2*, Ambati V. Raghava Reddy1, Paul Douglas Sanasi1, Raghubabu Korupolu2

1 Chemical Research and Development Department, Aurobindo Pharma Ltd, Survey No: 71&72, Indrakaran Village, Sangareddy Mandal, Medak district, Hyderabad – 502329, Andhra Pradesh, India
2 Department of Engineering Chemistry, A. U. College of Engineering (A), Andhra University, Visakhapatnam – 530 003, Andhra Pradesh, India

ARTICLE INFO
Received 12 April 2017
Accepted 25 April 2017

ABSTRACT
Azilsartan Kamedoxomil is an AT1-subtype angiotensin II receptor blocker (ARB). During the laboratory synthesis of Azilsartan Kamedoxomil, four related substances of Azilsartan Kamedoxomil were observed and identified. These were 2-Ethoxy-3-[[4-[2-[4-[[5-methyl-2-oxo-1,3-dioxol-4-yl]methyl]-5-oxo-1,2,4-oxadiazol-3-yl]phenyl]phenyl]methyl] benzimidazole-4-carboxylic acid (azilsartan N-medoxomil, 9), (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-[4-[[5-methyl-2-oxo-1,3-dioxol-4-yl]methyl]-5-oxo-1,2,4-oxadiazol-3-yl]phenyl]phenyl]methyl] benzimidazole-4-carboxylate (azilsartan dimedoxomil, 10), (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1'-(4,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)benzhydryl-4-yl)methyl]-2-methoxy-1H-benzimidazole-7-carboxylic acid (methoxy analogue of azilsartan medoxomil, 11), Methyl 1-((2'-amidobiphenyl-4-yl)methyl)-2-ethoxy-1H-benz[d]imidazole-7-carboxylate (amide methyl ester, 12). The present work describes the origin, synthesis and characterization of these related substances.

Keywords: Azilsartan Kamedoxomil, related substances, synthesis, characterization.

INTRODUCTION

Azilsartan Kamedoxomil is an AT1-subtype angiotensin II receptor blocker (ARB). Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme, and angiotensin II is the principal pressor agent of the rennin-angiotensin system [1,12], with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan Kamedoxomil blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Azilsartan Kamedoxomil, a prodrug form of azilsartan 2, was approved in 2011, and is used for the treatment of hypertension. It is marketed by Takeda under the brand name of Edarbi®. Azilsartan Kamedoxomil 1 is chemically known as (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]methyl]-1H-benzimidazole-7-carboxylate potassium salt. Azilsartan 2 is chemically known as 2-ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzhydryl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid.

Figure 1. Structures of Azilsartan Kamedoxomil 1 and Azilsartan 2

The presence of impurities in an Active Pharmaceutical Ingredient (API) will influence the quality and safety of the drug product. In the regulatory guidelines of the International Conference on Harmonization (ICH), it is recommended that impurities amounting to more than 0.1% [5] should be identified and characterized. Impurities are required to be in pure form to check the analytical performance characteristics such as specificity, linearity, range, accuracy, precision, limit of detection (LOD), limit of quantification, robustness, system suitability testing and relative retention factor [4].
During the process development of Azilsartan Kamedoxomil 1 in our laboratory, we observed the formation of four substances that are related to Azilsartan Kamedoxomil. These unknown related substances were identified, as well as monitored, and their structures were tentatively assigned on the basis of their fragmentation patterns in LC-MS. In the present work, the identified related substances of Azilsartan Kamedoxomil 1 were synthesized and then characterized by various spectroscopic techniques. Moreover, they were further confirmed by co-injection studies using qualitative HPLC analysis.

**EXPERIMENTAL**

Solvents and reagents were obtained from commercial source and used without purification. The IR spectra (9max, cm⁻¹) were recorded in solid state KBr dispersion, using a Perkin Elmer FT-IR spectrometer. The ¹H-NMR and ¹³C-NMR spectra were recorded on a Bruker-Avance 300 MHz, 500 MHz and a 125 MHz spectrometer. The chemical shifts were reported in δ/ppm relative to TMS. The mass spectra were then recorded on a API 2000 Perkin Elmer PE-Sciex mass spectrometer. The reactions were monitored by High pressure liquid chromatography (HPLC). Melting points were determined via a polman melting point apparatus (Model No MP96) by the open capillary method, and are uncorrected.

**2-Ethoxy-3-[[4-[2-[4-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-5-oxo-1,2,4-oxadiazol-3-yl]phenyl]phenyl]methyl]-benzimidazole-4-carboxylic acid (azilsartan N-medoxomil, 9)**

To a solution of Azilsartan (10 g, 21.92 mmol) in DMF (30 mL), we added medoxomil chloride (2.6 g, 17.53 mmol) at 25-30°C. The reaction mass was stirred for 1 h and the reaction mass was poured into DM water (300 mL). We then stirred the reaction mass for 1 h, filtered the product and adjusted pH to 4.0 with diluted hydrochloric acid. We stirred the product for 1 h, and filtered and dried the results: HPLC Purity: 97.59%; IR (KBr pellet): 3635, 2931, 1778, 1730, 1581, 1533, 1430, 1350, 1311, 1221, 1132 Cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆) δ: 7.728-7.744 (m, 3H, Ar); 7.172-7.187 (m, 2H, Ar); 7.156-7.172 (m, 1H, Ar); 7.172-7.187 (m, 3H, Ar); 7.007-7.034 (d, 2H, Ar); 5.635 (s, 2H, N-CH₂-Ar); 4.574-4.597 (q, 2H, COOCH₂); 4.152 (s, 3H, OCH₃); 2.17 (s, 3H, CH₃). Calcd: 555.1477; found: 555.1708.

**3-Ethoxy-3-[[4-[2-[4-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-5-oxo-1,2,4-oxadiazol-3-yl]phenyl]phenyl]methyl]-benzimidazole-4-carboxylic acid (7-carboxylate a (methoxy analogue of azilsartan medoxomil, 11)**

To a solution of methoxy analogue of azilsartan (10 g, 22.62 mmol) in dimethylacetamide (100 mL), we added medoxomil alcohol (4.11 g, 31.67 mmol) at 25-30°C. Then we cooled the reaction mass to -10°C to -15°C, and added p-toluensulfonic chloride (6.15 g, 32.34 mmol), DMAP (0.6 g, 4.97 mmol) and potassium carbonate (4.12 g, 29.8 mmol) at -10 to -15°C. Subsequently, we raised the reaction mass temperature to 10-15°C, stirred the reaction mass for 2 h, then poured the reaction mass into DM water (500 mL) and adjusted pH to 4.0 with diluted hydrochloric acid. We then stirred the product for 1 h, filtered and dried the results: a white compound 11 (10.2 g, 80%). The analytical results are as follows: HPLC Purity: 95.23%; IR (KBr pellet): 3662, 3010, 1785, 1731, 1617, 1229, 1109 Cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆) δ: 7.678-7.693 (m, 2H, Ar); 7.548-7.577 (m, 2H, Ar); 7.211-7.379 (m, 1H, Ar); 7.172-7.194 (m, 3H, Ar); 7.048-7.065 (d, 2H, Ar); 5.382 (s, 2H, N-CH₂-Ar); 5.061 (s, 2H, CH₂); 3.473 (s, 3H, CH₃). Calcd: 555.1776; found: 555.1776.

**Methyl 1-[(2’-amidobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (amide methyl ester 12)**

To a solution of BEC methyl ester (10 g, 24.33 mmol) in dimethyl sulfoxide (50 mL), we added a 30% w/w hydrogen peroxide (8.2 g, 72.92 mmol) solution at room temperature. We then stirred the reaction mixture for 2 h at 25-30°C, and poured the reaction mass into DM water (300 mL). The resulting solution was subsequently filtered and purified, giving the titled compound 12 (5 g, 50%). This was characterized as follows: HPLC purity: 97.59%; ¹H NMR (300 MHz, DMSO-d₆) δ: 7.172-7.187 (d, J = 8.1 Hz, 1H, Ar); 7.168 (s, 1H, Ar); 7.465-7.389 (m, 4H, Ar); 7.339-7.314 (m, 5H, Ar); 6.965-6.938 (d, J = 8.1 Hz, 2H, -CONH-); 5.518 (s, 2H, N-CH₂-Ar); 4.587-4.657 (q, 2H, OCH₂CH₂); 3.707 (s, 3H, OCH₃); 1.394-1.441 (t, J = 6.9, 4.8 Hz, 3H, OCH₃); IR (KBr pellet): 2994, 1768, 1717, 1614, 1542, 1281, 1153 Cm⁻¹.
RESULTS AND DISCUSSION

Several routes are available in literature [2,3,6-11,13, 15,16,20] for the synthesis of Azilsartan Kamedoxomil, the synthetic route [13] for azilsartan kamedoxomil being shown in Scheme 1. The process involves the reaction of methyl 1-((2’-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (BEC methyl ester, 5) with hydroxylamine hydrochloride in the presence of sodium methoxide, to produce amidoxime 6. The treatment of 6 with ethyl chloroformate in the presence of a base produces an intermediate 6a, which is cyclized in xylene at reflux to produce azilsartan methyl ester 7. Hydrolysis of 7 in aqueous sodium hydroxide subsequently produces Azilsartan 2.

Finally, azilsartan (2) treated with medoxomil alcohol (4) in the presence of tosyl chloride produces azilsartan medoxomil (8). Azilsartan medoxomil (8) is then treated with potassium 2-ethylhexanoate in acetone to produce azilsartan kamedoxomil 1, with a 60% yield.

Compound 9 is formed due to condensation of medoxomil chloride 3 at the isoxazole ring in azilsartan 2. Scheme 2. Synthesis of Azilsartan N-medoxomil

Compound 10 was confirmed by IR, Mass, NMR spectral data and co-injection with an authentic sample. The mass spectrum of compound 10 showed a molecular ion at m/z 569.1688. The NMR spectrum showed a singlet at δ 4.15, corresponding to –N-CH₂, and a broad singlet at δ 13, corresponding to –COOH. Furthermore, the infrared (IR) spectrum showed absorptions at 1614, corresponding to –C=O stretching – also confirming the assigned structure.

Origin and synthesis of compound 10 (Azilsartan dimedoxomil)

Compound 10 is formed due to the condensation of medoxomil chloride 3 at the isoxazole ring in azilsartan medoxomil 8.

Scheme 3. Synthesis of Azilsartan dimedoxomil

Compound 10 was confirmed by IR, Mass, NMR spectral data and co-injection with an authentic sample. The mass spectrum of compound 10 showed a molecular ion at m/z 681.1823. In addition, the NMR spectrum showed a singlet at δ 4.15, 5.11, 1.61 & 2.15 corresponding to –N-CH₂, –N-CH₃, –OH and –CH₂CH₂OCH₃, respectively.

The origin, synthesis and characterization of these related substances are described individually below. The synthetically prepared related substances were characterized by conventional spectroscopic studies, and the presence of these related substances in the Azilsartan Kamedoxomil batch was confirmed by spiking the related substances individually with Azilsartan Kamedoxomil. These studies confirmed the formation of related substances (9-12) during the standard manufacturing process of Azilsartan Kamedoxomil 1.
–O-CH₂ and two –CH₃ of the medoxomil group, while the Infrared (IR) spectrum showed absorptions at 1616, corresponding to –C=O stretching – also confirming the assigned structure 10.

**Origin and synthesis of compound 11 (Methoxy analogue of Azilsartan medoxomil)**

Compound 11 originates from BEC methyl ester raw material. The methoxy analogue of BEC methyl ester is present as an impurity in BEC methyl ester raw material, and may undergo all the reactions employed in the synthesis of Azilsartan medoxomil, to give compound 11.

**Scheme 4. Synthesis of Methoxy analogue of Azilsartan medoxomil 11**

Compound 11 was confirmed by IR, Mass, NMR spectral data and co-injection with an authentic sample. The mass spectrum of compound 11 showed a molecular ion at m/z 555.1776. What is more, the NMR spectrum showed a singlet at δ 12.42, corresponding to –NH, and the absence of –OCH₂ protons - also confirming the assigned structure. Moreover, the Infrared (IR) spectrum showed absorptions at 1617, corresponding to –C=O stretching – also confirming the assigned structure.

**Origin and synthesis of compound 12 (Amide methyl ester)**

Compound 12 is a major impurity in amidoxime methyl ester 6 preparation. It comes about because most of the reported methods for preparing amidoxime methyl ester 6 use an excess of hydroxylamine hydrochloride (18 to 25 mole equivalents). Hydroxylamine tends to decompose at higher temperature by giving ammonia as a by-product. This ammonia then reacts with BEC methyl ester 5, to give amide methyl ester 12 as a related substance. In our work, the amide methyl ester was independently prepared by treating BEC methyl ester 5 with hydrogen peroxide in dimethyl sulfoxide.

**Scheme 5: Synthesis of Amide methyl ester 12**

Compound 12 was confirmed by IR, Mass, NMR spectral data (experimental section 3.6) and co-injection with an authentic sample. The mass spectrum of compound 12 showed a molecular ion at m/z 430.1769. In comparison with BEC methyl ester 5, the NMR spectrum showed a singlet at δ 6.938 corresponding to -CONH₂, while the Infrared (IR) spectrum showed absorptions at 3518 and 1622, corresponding to -NH and -C=O stretching – also confirming the assigned structure.

**CONCLUSION**

The process related substances in Azilsartan Kamedoxomil were identified, synthesized and characterized by using ¹H NMR, ¹³C NMR, MS and IR techniques. Further, these related substances were co-injected with Azilsartan Kamedoxomil to confirm the retention time in HPLC. This related substances study of Azilsartan Kamedoxomil is, is hence, useful to the pharmaceutical industry.

**ABBREVIATIONS**

TsCl, Para-toluensulfonyl chloride; DMSO, dimethyl sulfoxide; DMAP, dimethylaminopyridine; DMAc, N,N-dimethylacetamide; DMF, N,N-dimethylformamide; TrCl, Trityl chloride; DSC, disuccinimidyl carbonate; TFA, trifluoroacetic acid; DIBOC, Di tert-butyl dicarbonate; DMC, dimethyl carbonate; DEC, diethyl carbonate; DPC, diphenyl carbonate; CDI, carbonyldiimidazole; ECF, ethyl chloroformate; HPLC. High pressure liquid chromatography; LCMS, Liquid chromatography-mass spectrometry.

**ACKNOWLEDGMENTS**

The authors gratefully acknowledge the management of Aurobindo Pharma Limited for allowing us to carry out this research work.

**REFERENCES**